A secondary cytoreductive surgery along with chemotherapy following recurrence in patients with epithelial ovarian cancer offered improved outcomes over treatment with chemotherapy alone.
Trabectedin plus pegylated liposomal doxorubicin offered clinical benefit in a real-life setting of patients with previously treated platinum-sensitive recurrent ovarian cancer.
TPIV200 stimulates T cells to attack ovarian and triple-negative breast tumor cells that over-express the folate receptor alpha protein.
A personalized cancer vaccine was well tolerated and was capable of inducing antitumor T-cell immunity in patients with recurrent ovarian cancer.
The FDA has granted approval of rucaparib for maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
A study presented at the SGO Annual Meeting found that PARP-7 amplification mutations are associated with prolonged survival among patients with platinum-sensitive ovarian cancer.
A single-institution study of patients with advanced/recurrent EOCs found no overall survival differences for Caucasians and minorities who had participated in a clinical trial.
PARP inhibitors are offering new treatment options for ovarian cancer patients with known mutations, but early-stage diagnosis is still elusive.
A registry study suggests that there may be a familial association between ovarian and testicular cancers.
A large study found no association between the use of metformin or statins and the incidence of ovarian cancer in women with type 2 diabetes.